Results of a phase II trial with cystemustine in advanced malignant melanoma. A trial of the EORTC Clinical Screening Group

Urosevic, V.; Chollet, Philippe; Adenis, Antoine; Chauvergne, J; Fargeot, P.; Roché, Henri; Kerbrat, Pierre; Lentz, M.A.; Fumoleau, P.; Chevallier, B.

doi:10.1016/0959-8049(95)00473-4

Cited by 6 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…WHO grade 3/4 toxicity for platelets observed in 41% of the present patients appeared unexpectedly frequent compared with the prior trial using 60 mg/m 2 (5%) [12]. It was comparable with the trial testing 90 mg/m 2 (43%) [13] for which a dose-limiting toxicity had meant a reduced dose of 60 mg/m 2 had to be used after the third cycle.…”

Section: Discussionsupporting

confidence: 84%

“…In the current study, the cystemustine OR (13.6%) was close to that observed in our two previous trials (11.3 and 9%), inspite of different dosages (90 and 60 mg/m 2 , respectively) and the fact that the cystemustine response rate was evaluated on overall patients treated in first and second line, and not separately [12,13]. Moreover, the OR of cystemustine of 13.6% (95% CI 3-35%) is comparable with other single treatments against previously treated MM.…”

Section: Discussionsupporting

confidence: 81%

“…We have already shown in the two previous trials [12,13] that drug toxicity was mainly hematologic, especially on platelets, and was sometimes dose limiting. WHO grade 3/4 toxicity for platelets observed in 41% of the present patients appeared unexpectedly frequent compared with the prior trial using 60 mg/m 2 (5%) [12].…”

Section: Discussionmentioning

confidence: 92%

“…In two phase II trials conducted by the EORTC Clinical Studies Group [12,13], with cystemustine at 60 and 90 mg/m 2 as a first-or second-line treatment, 25 and 54 patients, respectively, were enrolled. We have reported overall response rates (ORs) of 9 and 11%, respectively; 10 of 25 and 21 of 54 had previously been treated with other chemo-and/or immunotherapy.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Second-line chemotherapy of disseminated malignant melanoma with cystemustine at 60 mg/m2: a phase II trial

Thivat

Durando²,

D’Incan³

et al. 2005

Anti-Cancer Drugs

View full text Add to dashboard Cite

Nitrosoureas possess some anti-tumor activity as a single agent in metastatic melanoma (MM). In a phase II trial, we evaluated the anti-tumor effects of cystemustine chemotherapy, a new nitrosourea, as a second-line treatment. Patients were required to have histologic evidence of disseminated MM and had failed in first-line chemotherapy. Treatment comprised cystemustine given at a dose of 60 mg/m every 2 weeks by a 15-min infusion. From February 1997 to September 1999, 22 patients (median age 66 years) were enrolled and were assessable. Two complete responses, one partial response, three stable diseases and 16 progressions were observed, giving an overall response rate of 13.6%. Median duration of response was 10 months (range 4-63). Median survival of responders and non-responders was 11 and 4 months, respectively. However, hematological toxicity, particularly thrombopenia, was a limiting factor for one-third of patients. We conclude that cystemustine at 60 mg/m is active in patients who progressed after one line of chemotherapy in advanced disease, and offers the possibility of complete responses and long durations of these responses.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussionsupporting

confidence: 81%